Amgen Inc. $AMGN Position Boosted by Ironwood Investment Counsel LLC

Ironwood Investment Counsel LLC raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 15.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,373 shares of the medical research company’s stock after acquiring an additional 2,439 shares during the quarter. Ironwood Investment Counsel LLC’s holdings in Amgen were worth $6,014,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Anfield Capital Management LLC grew its stake in Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 70 shares in the last quarter. Dogwood Wealth Management LLC grew its stake in Amgen by 275.0% during the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 55 shares in the last quarter. Board of the Pension Protection Fund purchased a new position in Amgen during the 4th quarter valued at about $26,000. Manning & Napier Advisors LLC grew its stake in Amgen by 49.2% during the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 32 shares in the last quarter. Finally, Olistico Wealth LLC purchased a new position in Amgen during the 4th quarter valued at about $33,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.85% of the company’s stock.

Amgen Stock Performance

Shares of NASDAQ AMGN opened at $326.31 on Monday. The stock has a market cap of $176.10 billion, a price-to-earnings ratio of 22.71, a PEG ratio of 3.28 and a beta of 0.44. The business has a 50 day simple moving average of $349.17 and a 200 day simple moving average of $343.36. Amgen Inc. has a 52 week low of $267.73 and a 52 week high of $391.29. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts predict that Amgen Inc. will post 22.37 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 3.1%. Amgen’s payout ratio is presently 70.15%.

Analyst Ratings Changes

Several equities analysts have weighed in on AMGN shares. Sanford C. Bernstein cut Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 target price on the stock. in a research note on Tuesday, January 20th. Rothschild & Co Redburn lifted their target price on Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a research note on Wednesday, February 18th. Freedom Capital raised Amgen from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. The Goldman Sachs Group lifted their target price on Amgen from $415.00 to $425.00 and gave the company a “buy” rating in a research note on Friday, May 1st. Finally, Piper Sandler lowered their price target on Amgen from $432.00 to $427.00 and set an “overweight” rating for the company in a research note on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $356.15.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.